908 Devices (MASS) Competitors $6.49 +0.47 (+7.77%) As of 03:27 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MASS vs. EYPT, TRNS, ALNT, AEHR, CTKB, LAB, SENS, FEIM, QTRX, and QSIShould you be buying 908 Devices stock or one of its competitors? The main competitors of 908 Devices include Eyepoint Pharmaceuticals (EYPT), Transcat (TRNS), Allient (ALNT), Aehr Test Systems (AEHR), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Frequency Electronics (FEIM), Quanterix (QTRX), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry. 908 Devices vs. Its Competitors Eyepoint Pharmaceuticals Transcat Allient Aehr Test Systems Cytek Biosciences Standard BioTools Senseonics Frequency Electronics Quanterix Quantum-Si 908 Devices (NASDAQ:MASS) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, media sentiment, risk and analyst recommendations. Which has stronger valuation and earnings, MASS or EYPT? 908 Devices has higher revenue and earnings than Eyepoint Pharmaceuticals. 908 Devices is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio908 Devices$59.63M3.86-$72.21M-$0.54-11.90Eyepoint Pharmaceuticals$43.27M19.04-$130.87M-$2.68-4.46 Do insiders & institutionals believe in MASS or EYPT? 88.1% of 908 Devices shares are held by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are held by institutional investors. 23.7% of 908 Devices shares are held by company insiders. Comparatively, 4.5% of Eyepoint Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts rate MASS or EYPT? 908 Devices currently has a consensus target price of $8.00, indicating a potential upside of 24.51%. Eyepoint Pharmaceuticals has a consensus target price of $25.38, indicating a potential upside of 112.34%. Given Eyepoint Pharmaceuticals' higher probable upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than 908 Devices.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 908 Devices 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Eyepoint Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk & volatility, MASS or EYPT? 908 Devices has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500. Does the media prefer MASS or EYPT? In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than 908 Devices. MarketBeat recorded 3 mentions for Eyepoint Pharmaceuticals and 1 mentions for 908 Devices. Eyepoint Pharmaceuticals' average media sentiment score of 0.88 beat 908 Devices' score of 0.20 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 908 Devices 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Eyepoint Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is MASS or EYPT more profitable? 908 Devices has a net margin of -30.54% compared to Eyepoint Pharmaceuticals' net margin of -337.93%. 908 Devices' return on equity of -24.30% beat Eyepoint Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets 908 Devices-30.54% -24.30% -18.55% Eyepoint Pharmaceuticals -337.93%-63.80%-50.72% Summary908 Devices beats Eyepoint Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get 908 Devices News Delivered to You Automatically Sign up to receive the latest news and ratings for MASS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MASS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MASS vs. The Competition Export to ExcelMetric908 DevicesMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$230.40M$7.04B$5.81B$9.75BDividend YieldN/A1.30%3.84%4.09%P/E Ratio-11.9027.1630.8925.96Price / Sales3.8657.42469.53120.82Price / CashN/A21.6837.1558.38Price / Book1.556.919.116.37Net Income-$72.21M$176.42M$3.26B$265.56M7 Day Performance-3.09%0.48%1.82%1.79%1 Month Performance-8.99%-0.54%4.81%1.13%1 Year Performance59.03%13.03%31.07%21.04% 908 Devices Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MASS908 Devices3.4662 of 5 stars$6.49+7.8%$8.00+23.3%+42.7%$230.94M$59.63M-11.9360EYPTEyepoint Pharmaceuticals1.9174 of 5 stars$11.33+2.2%$25.38+124.0%+28.2%$780.94M$51.90M-4.23120TRNSTranscat2.836 of 5 stars$82.24+0.9%$112.20+36.4%-29.7%$766.48M$278.42M57.511,245Analyst ForecastALNTAllient2.8755 of 5 stars$44.56+2.4%$35.00-21.5%+110.0%$755.29M$529.97M51.812,525News CoverageAnalyst RevisionAEHRAehr Test Systems1.916 of 5 stars$19.39+5.9%N/A+22.0%$580.15M$58.97M-149.1490Options VolumeCTKBCytek Biosciences3.5248 of 5 stars$4.06+1.2%$5.60+37.9%-25.5%$516.51M$200.45M-81.20500Positive NewsLABStandard BioTools2.5558 of 5 stars$1.27+3.3%$1.55+22.0%-38.1%$482.37M$174.43M-3.97620Gap UpSENSSenseonics2.4156 of 5 stars$0.47-0.7%$1.55+230.1%+6.2%$382.49M$25.47M-3.6190News CoveragePositive NewsFEIMFrequency Electronics1.3238 of 5 stars$28.38-7.8%N/A+110.5%$276.14M$69.81M11.49200QTRXQuanterix2.4013 of 5 stars$4.95+8.3%$11.75+137.4%-63.2%$230.03M$137.42M-2.72460Positive NewsQSIQuantum-Si2.2846 of 5 stars$1.09-0.9%$3.48+218.8%+9.9%$220.71M$3.06M-1.60150 Related Companies and Tools Related Companies Eyepoint Pharmaceuticals Alternatives Transcat Alternatives Allient Alternatives Aehr Test Systems Alternatives Cytek Biosciences Alternatives Standard BioTools Alternatives Senseonics Alternatives Frequency Electronics Alternatives Quanterix Alternatives Quantum-Si Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MASS) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The “top secret” DeFi play Our #1 Coin Report reveals which protocol is building this institutional bridge...Crypto 101 Media | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 908 Devices Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 908 Devices With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.